期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil
1
作者 Jingjing Cao Jun Sun +1 位作者 Shujuan Zhao peizhi ma 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2020年第10期729-733,共5页
Baloxavir marboxil is a polymerase acidic(PA)endonuclease inhibitor,which is approved by the U.S Food and Drug Administration(FDA)on October 25,2018,for the treatment of uncomplicated influenza patients aged 12 years ... Baloxavir marboxil is a polymerase acidic(PA)endonuclease inhibitor,which is approved by the U.S Food and Drug Administration(FDA)on October 25,2018,for the treatment of uncomplicated influenza patients aged 12 years and older.In the present work,we reviewed the pharmacodynamics,pharmacokinetics,drug interactions,clinical trials and adverse reactions of baloxavir marboxil. 展开更多
关键词 Baloxavir marboxil PHARMACODYNAMICS PHARMACOKINETICS Adverse reactions
原文传递
Research progress of sacubitril/valsartan in heart failure patients with preserved ejection fraction 被引量:2
2
作者 Jingjing Cao Shujuan Zhao +1 位作者 Chenglong Zhao peizhi ma 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2022年第6期471-477,共7页
With the launch of sacubitril/valsartan(ARNI),there are new options for the treatment of heart failure(HF).However,ARNI is currently only used in HF patients with reduced ejection fraction(HFrEF).No evidence shows tha... With the launch of sacubitril/valsartan(ARNI),there are new options for the treatment of heart failure(HF).However,ARNI is currently only used in HF patients with reduced ejection fraction(HFrEF).No evidence shows that no modern treatment can reduce mortality in HF patients with preserved ejection fraction(HFpEF).Therefore,it is urgently necessary clarify whether ARNI can be used in the treatment of HFpEF.In the present study,we summarized the research progress of ARNI in the treatment of HFpEF. 展开更多
关键词 Preserved ejection fraction Reduced ejection fraction Sacubitril/valsartan
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部